Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group
暂无分享,去创建一个
M. Humbert | D. Furst | O. Kowal‐Bielecka | C. Denton | M. Matucci-Cerinic | O. Distler | J. Seibold | J. Avouac | C. Opitz | D. Pittrow | L. Rubin | P. Nash | I. Foeldvari | F. Behrens | D. Huscher | O. Kowal-Bielecka
[1] Y. Allanore,et al. Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis , 2009, The Journal of Rheumatology.
[2] C. Strange,et al. Limitations to the 6-Minute Walk Test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma , 2009, The Journal of Rheumatology.
[3] J. Seibold,et al. The 6-minute walk test in scleroderma--how measuring everything measures nothing. , 2008, Rheumatology.
[4] Oliver Distler,et al. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. , 2008, Arthritis and rheumatism.
[5] R. Barst,et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. , 2007, The Journal of rheumatology.
[6] R. Barst,et al. Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease , 2007, Annals of the rheumatic diseases.
[7] Y. Allanore,et al. New therapeutic strategies in the management of systemic sclerosis , 2007, Expert opinion on pharmacotherapy.
[8] A. L. de Sá Pinto,et al. Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement , 2007, Scandinavian journal of rheumatology.
[9] D. Furst,et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test , 2006, Annals of the rheumatic diseases.
[10] M. Humbert,et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions , 2006, Annals of the rheumatic diseases.
[11] Y. Allanore,et al. Radiological hand involvement in systemic sclerosis , 2006, Annals of the rheumatic diseases.
[12] C. Denton,et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era , 2005, Heart.
[13] S. Rich,et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. , 2004, Chest.
[14] M. Suarez‐Almazor,et al. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. , 2003, The Journal of rheumatology.
[15] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[16] P. Tugwell,et al. The OMERACT filter for Outcome Measures in Rheumatology. , 1998, The Journal of rheumatology.
[17] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[18] R. Barst,et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. , 2007, Annals of the rheumatic diseases.
[19] P. Sampaio-Barros,et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. , 2007, Chest.
[20] F. Balsano,et al. Pulmonary hypertension is associated with impaired exercise performance in patients with systemic sclerosis , 2000, Scandinavian journal of rheumatology.